Analysis of the reflexed liquid biopsy samples in this study revealed variants in genes commonly mutated in prostate cancer including TP53 (43.2%), AR (28.8%), TMPRSS2 (14.4%), CDK12 (9.0%), BRCA2 (2.7%), and PTEN (13.5%). This evidence concerns the gene BRCA2 and prostate cancer.